Prognostic Significance of HER-2 Expression in Gastric Cancer
- 1 May 2021
- journal article
- research article
- Published by Ordu University in Black Sea Journal of Health Science
- Vol. 4 (2) , 52-57
Abstract
In gastric cancers we purposed to examine the relationship between age, gender, invasion depth, lymph node metastasis,lymphovascular invasion, Lauren's classification, presence of perineural invasion and the expression of Human Epidermal GrowthReceptor (HER-2) by immunohistochemical (IHC) and dual-color silver-enhanced in situ hybridization (D-SISH) method. In our study,242 gastric resection materials that were studied HER-2 by IHC and/or D-SISH method referred to our department between January2014 and December 2017 for malignancy were included. The relationship between HER-2 expression rate and prognostic parameterswas investigated. No statistical relation was found between age and gender and HER-2 positivity in either method. No statisticallysignificant results were obtained between lymphovascular invasion, lymph node metastasis, presence of perineural invasion, depth ofinvasion and Lauren classification, and HER-2 positivity by immunohistochemical and D-SISH method. In our study, no statisticallysignificant results were obtained between important prognostic parameters and HER-2 positivity with either IHC or D-SISH method. In24.1% of the cases that were HER-2 positive by IHC, positivity was not observed with the D-SISH method. Also, 20.8% of the casesreported as immunohistochemically uncertain (equivocal) were seen as positive by the D-SISH method. Based on all these results, wewould like to state that HER-2 positivity / negativity determined by IHC can be changed by the D-SISH method. In addition, although itwas shown in our study that HER-2 has no prognostic significance in gastric carcinomas, it is reported in studies in the literature thatthe addition of Trastuzumab to chemotherapy increases survival. For this reason, we think that it would be more beneficial to applythe IHC and D SISH method together to obtain the true HER-2 result.Keywords
This publication has 18 references indexed in Scilit:
- Clues and Pitfalls on HER2 evaluationThe Anatolian Journal of General Medical Research, 2015
- Burden of cancer in Malawi; common types, incidence and trends: National population-based cancer registryBMC Research Notes, 2012
- Anti-HER agents in gastric cancer: from bench to bedsideNature Reviews Gastroenterology & Hepatology, 2011
- Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancerLaboratory Investigation, 2011
- Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue MicroarraysAnnals of Surgical Oncology, 2011
- Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancerClinical and Translational Oncology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 2008
- Survival After Gastric Adenocarcinoma Resection: Eighteen-Year Experience at a Single InstitutionJournal of Gastrointestinal Surgery, 2005
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnnals of Oncology, 2005